Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionPalo Alto Investors LP
Latest Disclosed Ownership230,453 shares
Latest Disclosed Value $ 6,846,759
Palo Alto Investors LP reports 108.14% increase in ownership of TVTX / Travere Therapeutics, Inc.

On May 15, 2026 - Palo Alto Investors LP filed a 13F-HR form disclosing ownership of 230,453 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $6,846,759 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 110,719 shares of Travere Therapeutics, Inc.. This represents a change in shares of 108.14% during the quarter. The current value of the position is $10,416,476 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 230,453 119,734 108.14 6,847 61.84 1.0471
2026-02-17 2025-12-31 13F TRAVERE THERAPEUTICS COM SHS 89422G107 110,719 0 0.00 4,231 59.86 0.5889
2025-11-14 2025-09-30 13F TRAVERE THERAPEUTICS COM SHS 89422G107 110,719 0 0.00 2,646 61.54 0.4897
2025-08-14 2025-06-30 13F TRAVERE THERAPEUTICS COM SHS 89422G107 110,719 0 0.00 1,639 -17.44 0.3486
2025-05-15 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 110,719 0 0.00 1,984 2.90 0.3778
2025-02-14 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 110,719 0 0.00 1,929 24.55 0.2989
2024-11-14 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 110,719 0 0.00 1,549 70.11 0.2012
2024-08-14 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 110,719 0 0.00 910 6.68 0.1055
2024-05-15 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 110,719 0 0.00 854 -14.27 0.0963
2024-02-15 2023-12-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 110,719 -55,350 -33.33 995 -32.95 0.0897
2024-02-14 2023-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 110,719 995
2023-11-14 2023-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 166,069 0 0.00 1,485 -41.80 0.1405
2023-08-14 2023-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 166,069 0 0.00 2,551 -31.71 0.2061
2023-05-15 2023-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 166,069 0 0.00 3,735 6.93 0.3094
2023-02-14 2022-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 166,069 0 0.00 3,492 -14.66 0.2978
2022-11-14 2022-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 166,069 0 0.00 4,092 1.69 0.3235
2022-08-15 2022-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 166,069 0 0.00 4,024 -5.98 0.3507
2022-05-16 2022-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 166,069 0 0.00 4,280 -16.97 0.3309
2022-02-14 2021-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 166,069 0 0.00 5,155 28.01 0.3294
2021-11-15 2021-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 166,069 0 0.00 4,027 66.20 0.2431
2021-08-16 2021-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 166,069 0 0.00 2,423 -41.57 0.1335
2021-05-17 2021-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 166,069 8,169 5.17 4,147 -3.65 0.2363
2021-02-16 2020-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 157,900 0 0.00 4,304 47.65 0.2256
2020-11-16 2020-09-30 13F RETROPHIN COM 761299106 157,900 110,900 235.96 2,915 203.96 0.1600
2020-08-14 2020-06-30 13F RETROPHIN COM 761299106 47,000 0 0.00 959 39.80 0.0576
2020-05-15 2020-03-31 13F RETROPHIN COM 761299106 47,000 47,000 686 0.0574
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.